In vitro Cytotoxicity of 17-Oxo-5-androsten-3β-yl esters against Liver, Neuroblastoma and Colon Cancer Cell Lines

Authors

  • Neelima Dhingra Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India

Abstract

A tumor is abnormal growth of body tissue and steroidal derivatives represent a distinct class of antineoplastic agents. Positioning of the oxo group on the parental steroid skeleton has significant effect on the antineoplastic activity profile of the compounds.  Recent work from our laboratory has also demonstrated the effectiveness of 17-oxo-5-androsten-3β-yl ester derivatives as potential antiproliferative agents and 5-alpha reductase inhibitors. The current study was undertaken to investigate the cytotoxicity using sulforhodamine B dye (SRB ) assay  of the synthesized derivative against six more human cancer cell lines at the  1X 10-5 m (single dose).

 

Keywords: Cytotoxicity, Human cancer cell lines, Steroids, Sulphorodamine B6

Cite this Article

Neelima Dhingra. In vitro cytotoxicity of 17-Oxo-5-androsten-3β-yl esters against liver, neuroblastoma and colon cancer cell lines. Research & Reviews: A Journal of Drug Design & Discovery. 2016; 3(3): 23–27p.

Downloads

Published

2019-03-04

Issue

Vol. 3 No. 3 (2016)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.